CAPECITABINE PLUS CISPLATIN (XP) COMBINATION CHEMOTHERAPY IS MANAGEABLE AND EFFECTIVE FOR ADVANCED GASTRIC CANCER PATIENTS IN CLINICAL PRACTICE

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Capecitabine plus cisplatin (XP) combination chemotherapy is one of the global standard regimens as first-line for HER2-negative AGC. But in Japan, S-1 plus cisplatin (SP) combination chemotherapy is regarded as a standard regimen by SPIRITS trial. So, few data are existed for the results of XP in Japan.

Methods

Thirteen AGC patients were treated XP (capecitabine 2000 mg/m2 on day 1–14, CDDP 80 mg/m2 on day 1, q3w) as first-line in clinical practice. We estimated response rate (RR), time to treatment failure (TTP), progression-free survival, overall survival (OS), and toxic effects.

Results

Between December 2010 and November 2011, 13 AGC patients were treated XP in our hospital. PS0/1/2: 8/4/1, median age: 70 years old (22–80), gender: m/f: 5/8, differentiated type/undifferentiated type: 5/8. Median courses were 3 (1–6). The most common grade 3/4 adverse events were neutropenia (23%), anemia (8%), and AST elevated (8%). Two patients died within 30 days after the last administration due to disease progression. In seven patients who had measurable lesions, five patients were partial response (71%). Median PFS were 188 days and median OS was not reached.

Conclusions

XP combination therapy was feasible and effective as first-line chemotherapy for AGC in clinical practice in Japan.

Related Topics

    loading  Loading Related Articles